SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.
August 27, 2024
SyVentoBioTech presenting our Fill&Finish Expertise at CPHI Milan.SyVentoBioTech is excited to announce our participation at CPHI Milan, taking place in October 8-10 at Fiera Milano. CPHI Milan as a premier platform for the pharmaceutical industry, brings together a global network of experts and decision-makers from 166+ countries all over the globe and we are proud to join this vibrant community and contribute to the […]